TY  - JOUR
AU  - Baumeister, Hannah
AU  - Gellersen, Helena M
AU  - Polk, Sarah E
AU  - Lattmann, René
AU  - Wuestefeld, Anika
AU  - Wisse, Laura E M
AU  - Glenn, Trevor
AU  - Yakupov, Renat
AU  - Stark, Melina
AU  - Kleineidam, Luca
AU  - Roeske, Sandra
AU  - Marcos Morgado, Barbara
AU  - Esselmann, Hermann
AU  - Brosseron, Frederic
AU  - Ramirez, Alfredo
AU  - Lüsebrink, Falk
AU  - Synofzik, Matthis
AU  - Schott, Björn H
AU  - Schmid, Matthias C
AU  - Hetzer, Stefan
AU  - Dechent, Peter
AU  - Scheffler, Klaus
AU  - Ewers, Michael
AU  - Hellmann-Regen, Julian
AU  - Ersözlü, Ersin
AU  - Spruth, Eike Jakob
AU  - Gemenetzi, Maria
AU  - Fliessbach, Klaus
AU  - Bartels, Claudia
AU  - Rostamzadeh, Ayda
AU  - Glanz, Wenzel
AU  - Incesoy, Enise I
AU  - Janowitz, Daniel
AU  - Rauchmann, Boris Stephan
AU  - Kilimann, Ingo
AU  - Sodenkamp, Sebastian
AU  - Coenjaerts, Marie
AU  - Spottke, Annika
AU  - Peters, Oliver
AU  - Priller, Josef
AU  - Schneider, Anja
AU  - Wiltfang, Jens
AU  - Buerger, Katharina
AU  - Perneczky, Robert
AU  - Teipel, Stefan
AU  - Laske, Christoph
AU  - Wagner, Michael
AU  - Ziegler, Gabriel
AU  - Jessen, Frank
AU  - Düzel, Emrah
AU  - Berron, David
TI  - Disease stage-specific atrophy markers in Alzheimer's disease.
JO  - Alzheimer's and dementia
VL  - 21
IS  - 7
SN  - 1552-5260
CY  - Hoboken, NJ
PB  - Wiley
M1  - DZNE-2025-00886
SP  - e70482
PY  - 2025
AB  - Structural magnetic resonance imaging (MRI) often lacks diagnostic, prognostic, and monitoring value in Alzheimer's disease (AD), particularly in early disease stages. To improve its utility, we aimed to identify optimal atrophy markers for different intended uses.We included 363 older adults; cognitively unimpaired individuals who were negative or positive for amyloid beta (Aβ) and Aβ-positive patients with subjective cognitive decline, mild cognitive impairment, or dementia of the Alzheimer type. MRI and neuropsychological assessments were administered annually for up to 3 years.Accelerated atrophy of medial temporal lobe subregions was evident already during preclinical AD. Symptomatic disease stages most notably differed in their hippocampal and parietal atrophy signatures. Atrophy-cognition relationships varied by intended use and disease stage.With the appropriate marker, MRI can detect abnormal atrophy already during preclinical AD. To optimize performance, atrophy markers should be tailored to the targeted disease stage and intended use.Subregional atrophy markers detect ongoing atrophy in preclinical Alzheimer's disease (AD). Subjective cognitive decline in preclinical AD links to manifest atrophy. Optimal atrophy markers differ by the disease stage and intended use.
KW  - Humans
KW  - Alzheimer Disease: pathology
KW  - Alzheimer Disease: diagnostic imaging
KW  - Atrophy: pathology
KW  - Magnetic Resonance Imaging
KW  - Male
KW  - Female
KW  - Aged
KW  - Cognitive Dysfunction: pathology
KW  - Cognitive Dysfunction: diagnostic imaging
KW  - Neuropsychological Tests
KW  - Biomarkers
KW  - Amyloid beta-Peptides
KW  - Brain: pathology
KW  - Brain: diagnostic imaging
KW  - Disease Progression
KW  - Aged, 80 and over
KW  - Hippocampus: pathology
KW  - imaging biomarker (Other)
KW  - longitudinal atrophy (Other)
KW  - magnetic resonance imaging (Other)
KW  - medial temporal lobe (Other)
KW  - parietal lobe (Other)
KW  - Biomarkers (NLM Chemicals)
KW  - Amyloid beta-Peptides (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:40691867
DO  - DOI:10.1002/alz.70482
UR  - https://pub.dzne.de/record/280047
ER  -